AbbVie’s Rinvoq hits targets in atopic dermatitis trial
The JAK inhibitor significantly improved skin clearance and reduced itch
Read Moreby Selina McKee | Jul 22, 2020 | News | 0
The JAK inhibitor significantly improved skin clearance and reduced itch
Read Moreby Anna Smith | Oct 16, 2019 | News | 0
There is currently a “critical need” for additional treatment options for atopic dermatitis.
Read Moreby Anna Smith | Aug 6, 2019 | News | 0
33% of patients who received Dupixent every four weeks achieved clear or almost clear skin.
Read Moreby Anna Smith | May 16, 2019 | News | 0
The company’s Janus kinase 1 has met all co-primary and secondary endpoints in a pivotal Phase III study.
Read Moreby Selina McKee | Sep 11, 2018 | News | 0
The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.
Read Moreby Selina McKee | Jul 12, 2018 | News | 0
GlaxoSmithKline has sold rights to an experimental therapy being developed for psoriasis and dermatitis to Dermavant in a deal worth $330 million.
Read Moreby Selina McKee | Dec 8, 2016 | News | 0
European regulators have accepted for review Regeneron and Sanofi’s application to market Dupixent for the treatment of certain adults with atopic dermatitis.
Read Moreby Selina McKee | Jun 7, 2016 | News | 0
Sanofi and Regeneron’s experimental therapy dupilumab has hit primary and secondary targets in a late-stage trial assessing its effectiveness in patients with poorly controlled atopic dermatitis.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
